Orgenesis

Orgenesis is a biotechnology company headquartered in Germantown, Maryland, that focuses on making cell and gene therapies (CGTs) more accessible and affordable. The company has developed the POCare Platform, which includes three primary components: Therapies, Technologies, and Network. This platform aims to lower costs and standardize high-quality CGTs, regardless of patient location. Orgenesis has spent over a decade addressing the challenges of processing personalized CGTs locally. The POCare Platform includes Orgenesis Mobile Processing Units and Labs™ (OMPUL™), which are fully integrated, closed-loop bioprocessing units designed to simplify therapy production and reduce logistic complexity. The platform also features a global quality harmonization system, a unified supply chain, centralized data management, automated processing systems, and standardized training programs. Orgenesis partners with early-stage biotechnology developers to bring development and validation in-house, creating a pipeline of owned, licensed, and partnered therapies. The POCare Network collaborates with global academia, research, and hospital partners to enable the development, production, and distribution of advanced therapies directly at the point of care. Orgenesis’ pipeline includes therapies for immuno-oncology, viral diseases, metabolic and autoimmune diseases, vascular and musculoskeletal diseases, and kidney disease. The company has development and service centers in the United States, Belgium, Israel, and South Korea.